Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
PHASE2CompletedINTERVENTIONAL
Enrollment
30
Participants
Timeline
Start Date
September 30, 2005
Conditions
Heart Failure, CongestiveRenal Insufficiency
Interventions
DRUG
KW-3902IV
Trial Locations (6)
Unknown
San Diego
Baltimore
Ayer
Boston
Kalamazoo
Tullahoma
All Listed Sponsors
collaborator
Merck Sharp & Dohme LLC
INDUSTRY
lead
NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
INDUSTRY
NCT00159614 - Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment | Biotech Hunter | Biotech Hunter